type 2 diabetes
Conditions
Interventions
no physical exercise habit
physical exercise habit
no physical exercise habit with treatment of 20mg/day teneligliptin
physical exercise habit with treatment of 20mg/day teneligliptin
Sponsors
Geriatric Medicine, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The patients with type 2 diabetes, 70 years of age and older 2) The subjects without previous cardiovascular or respiratory diseases and abnormality of the electrocardiogram 3) The subjects with poorly-controlled diabetes (HbA1c 6.0-8.0%) by: 1. sulfonylureas with diet and exercise 2. thiazolidinediones with diet and exercise 3. alpha-glucosidase inhibitors with diet and exercise
Exclusion criteria
Exclusion criteria: 1) the patients wiht type 1 diabetes 2) the subjects whose HbA1cs are below 6.0% or over 8.0% 3) the subjects who cannot reduce the dosage of sulfonylureas (using more than 2mg/day of glimepiride, 1.25mg/day of glibenclamide, 40mg of gliclazide 4) the subjects with poorly-controlled hypertension (systolic blood pressure >160mmHg) 5) the subjects with a diagonosis of effort angina, chronic heart failure(class II of NHYA classification and more) and tachyarrhythmia 6) the subjects with a diagnosis of chronic respiratory failure(class II of Hugh-Jones classification and more) 7) the subjects who cannot pedal a bike for about 30min 8) the subjects with shorter time of one leg standing (<15sec) 9) the subjects in active treatment for hypothyroidism 10) the subjects with severe liver dysfunction: more than 100IU/L of AST and ALT level 11) the subjects already enrolled in other clinical trial 12) the subjects found offensive by attending physicians for this research
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The change in 1) fasting blood glucose, HbA1c 2) BMI 3) serum creatinine level 4) plasma IL-6 concentration 5) plasma active GLP-1 concentration 6) intima media thickness (IMT) by carotid ultrasonography | — |
Primary
| Measure | Time frame |
|---|---|
| 1) The changes in plasma IL-6 or GLP-1 concentration after training in the subjects with or without regular exercise 2) The changes in plasma IL-6 or GLP-1 concentration at rest in the subjects treated with or without teneligliptin, and the enchancing effect on the changes in plasma IL-6 or GLP-1 concentration by the treatment of teneligliptin | — |
Countries
Japan
Contacts
Public ContactKen Sugimoto
Osaka University Graduate School of Medicine Geriatri Medicine
Outcome results
None listed